[Cardiac arrhythmias. I. Pathogenesis and clinical significance].
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D001145:Arrhythmias, Cardiac / Q000139:chemically induced / Q000145:classification / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology / Q000503:physiopathology; D001281:Atrial Fibrillation / Q000209:etiology / Q000503:physiopathology; D001282:Atrial Flutter / Q000503:physiopathology; D001919:Bradycardia / Q000503:physiopathology; D005117:Cardiac Complexes, Premature / Q000503:physiopathology; D004071:Digitalis Glycosides / Q000009:adverse effects / Q000627:therapeutic use; D006327:Heart Block / Q000503:physiopathology; D006329:Heart Conduction System / Q000503:physiopathology; D006801:Humans; D007008:Hypokalemia / Q000150:complications; D008012:Lidocaine / Q000627:therapeutic use; D008564:Membrane Potentials; D009203:Myocardial Infarction / Q000150:complications; D009206:Myocardium / Q000473:pathology; D010672:Phenytoin / Q000627:therapeutic use; D011342:Procainamide / Q000627:therapeutic use; D011802:Quinidine / Q000627:therapeutic use; D011817:Rabbits; D013610:Tachycardia / Q000503:physiopathology; D013614:Tachycardia, Paroxysmal / Q000503:physiopathology
D000319:Adrenergic beta-Antagonists; D000889:Anti-Arrhythmia Agents; D004071:Digitalis Glycosides; D010672:Phenytoin; D008012:Lidocaine; D011802:Quinidine; D011342:Procainamide
Kardiale Rhythmusstörungen. I. Pathogenese und klinische Bedeutung.